Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. (Q34062445)

30 July 2017

1 reference

title

Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. (English)

1 reference

30 July 2017

S Daya

1

1 reference

PubMed ID

11034767

30 July 2017

J Gunby

series ordinal

2

1 reference

30 July 2017

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

1 reference

30 July 2017

4

1 reference

30 July 2017

CD002810

1 reference

Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified urinary FSH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): A comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Why do we need systematic overviews of randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002810

10.1002/14651858.CD002810

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11034767